Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Organogenesis, Inc. (AMEX:ORG)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 13Earnings Announcement
Location
150 Dan Road
Canton, MA 02021
Phone: (781) 575-0775
Fax: (781) 575-0440
Email: investor-relations@organo.com
Employees (last reported count): 236
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 600 SmallCap
Ownership
·Insider and 5%+ Owners: 21%
·Over the last 6 months:
 · 3 insider buys; 22.0K shares (0.3% of insider shares)
 · one insider sell; 35.0K shares
  (0.5% of insider shares)
·Institutional: 32% (41% of float)
(152 institutions)
·Net Inst. Buying: 209.0K shares (+1.83%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Organogenesis, Inc. is a tissue engineering company that designs, develops and manufactures medical products containing living cells and/or natural connective tissue. The Company is the developer and manufacturer of the only mass-produced product containing living human cells to gain Food and Drug Administration (FDA) marketing approval. The Company's lead product, Apligraf, a cellular, bi-layered skin substitute, is FDA approved for the treatment of venous leg ulcers and diabetic foot ulcers; Novartis Pharma AG has global Apligraf marketing rights. Organogenesis is leveraging its FortaFlex bioengineered collagen matrix technology into a family of products, and has recently achieved marketing clearance for its FortaPerm surgical sling and PuraPly wound dressing. The Organogenesis research pipeline includes the Vitrix living dermal replacement, a coronary vascular graft and a liver assist device.
More from Market Guide: Expanded Business Description

Financial Summary
Organogenesis, Inc. designs, develops and manufactures medical therapeutics containing living cells and/or natural connective tissue. For the six months ended 6/30/01, total revenues fell 38% to $4.6 million. Net loss before accounting change increased 84% to $15.1 million. Revenues reflect the absence of a $5 million milestone payment from Novartis related to diabetic foot ulcers. Loss also reflects $1.2 million in severance expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Albert Erani, 60
Chairman
--  --  
Michael Sabolinski, M.D., 45
Pres, CEO, Director
$283K$105K
John Arcari, 55
CFO, VP of Fin. and Admin., Sec., Treasurer
119K--  
Nancy Parenteau, Ph.D., 47
Sr. VP of R&D and CSO
273K--  
Paul DiCicco, 49
VP-Operations
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:ORGAs of 31-Aug-2001
Price and Volume
52-Week Low
on 3-Apr-2001
$6.70 
Recent Price$7.60 
52-Week High
on 5-Sep-2000
$16.438
Beta1.82 
Daily Volume (3-month avg)93.3K
Daily Volume (10-day avg)101.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-53.3%
52-Week Change
relative to S&P500
-37.3%
Share-Related Items
Market Capitalization$264.4M
Shares Outstanding34.8M
Float27.5M
Dividends & Splits
Annual Dividendnone 
Last Split: 5 for 4 on 30-Apr-1998
Per-Share Data
Book Value (mrq)-$0.51 
Earnings (ttm)-$0.85 
Earnings (mrq)-$0.25 
Sales (ttm)$0.22 
Cash (mrq)$0.07 
Valuation Ratios
Price/BookN/A 
Price/EarningsN/A 
Price/Sales (ttm)35.25 
Income Statements
Sales (ttm)$7.43M
EBITDA (ttm)-$23.9M
Income available to common (ttm)-$29.2M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-100.92%
Return on EquityN/A 
Financial Strength
Current Ratio (mrq)1.03 
Debt/EquityN/A 
Total Cash (mrq)$2.55M
Short Interest
As of 8-Aug-2001
Shares Short2.35M
Percent of Float8.5%
Shares Short
(Prior Month)
0 
Short Ratio35.59 
Daily Volume66.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.